Key terms

About VTRS

Viatris, Inc. is a global healthcare company, which engages in the provision of access to medicines and sustainable operations. It also offers support services such as diagnostic clinics, educational seminars, and digital tools. The firm operates through the following segments: Developed Markets, Greater China, JANZ, and Emerging Markets. The Developed Markets segment consists of operations primarily in North America and Europe. The Greater China segment includes operations in mainland China, Taiwan and Hong Kong. The JANZ segment consists of operations in Japan, Australia and New Zealand. The Emerging Markets segment encompasses operations with developing markets and emerging economies including countries in Asia, the Middle East, South and Central America, Africa and Eastern Europe. The company was founded on February 14, 2019 and is headquartered in Canonsburg, PA.

Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
     
52-week range
     
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date

Key terms

Smart score

Latest VTRS news

Apr 03 9:56am ET Early notable gainers among liquid option names on April 3rd Apr 01 7:16am ET Ocuphire Pharma announces U.S. commercial launch of RYZUMVI Apr 01 7:05am ET Viatris announces U.S. commercial launch of Ryzumvi Mar 28 6:41am ET Viatris price target raised to $13 from $11 at Piper Sandler Mar 28 5:31am ET Analysts Conflicted on These Healthcare Names: Alphatec Holdings (ATEC) and Viatris (VTRS) Mar 15 11:45am ET Viatris call volume above normal and directionally bullish Feb 29 6:32am ET Barclays Sticks to Their Sell Rating for Viatris (VTRS) Feb 29 5:46am ET Viatris Sell Rating Maintained Amid EBITDA Concerns and Uncertain Growth Prospects Feb 28 7:32am ET VTRS Earnings: Viatris Trends Higher on Q4 Numbers, $1B Buyback Boost Feb 28 6:40am ET Viatris sees FY24 adjusted EPS $2.70-$2.85, consensus $2.81 Feb 28 6:37am ET Viatris reports Q4 EPS (64c), consensus 65c Feb 28 5:58am ET Viatris, Idorsia enter agreements for global research and development Feb 28 1:30am ET SPY ETF Update, 2/28/2024 Feb 26 1:09am ET SPY ETF Update, 2/26/2024 Feb 22 1:07am ET SPY ETF Update, 2/22/2024 Feb 20 12:28am ET SPY ETF Update, 2/20/2024 Feb 16 12:20am ET SPY ETF Update, 2/16/2024 Feb 14 4:43pm ET Greenlight buys Alight, exits Southwestern in Q4 Feb 08 12:25am ET SPY ETF Update, 2/8/2024 Feb 01 11:48pm ET SPY ETF Update, 2/2/2024 Jan 31 11:45am ET Viatris call volume above normal and directionally bullish Jan 29 2:55pm ET Viatris put volume heavy and directionally bearish Jan 29 1:53am ET SPY ETF Update, 1/29/2024 Jan 25 12:36am ET SPY ETF Update, 1/25/2024 Jan 23 3:05pm ET Viatris call volume above normal and directionally bullish Jan 23 12:51am ET SPY ETF Update, 1/23/2024 Jan 22 2:05pm ET Viatris call volume above normal and directionally bullish Jan 22 11:46am ET Greenlight announced new Alight, Viatris positions, Bloomberg says Jan 19 12:28am ET SPY ETF Update, 1/19/2024 Jan 17 12:28am ET SPY ETF Update, 1/17/2024 Jan 15 7:13am ET SPY ETF Update, 1/15/2024

No recent press releases are available for VTRS

VTRS Financials

1-year income & revenue

Key terms

VTRS Forecasts

analyst rating

  • buy
  • hold
  • sell

We're sorry, but this
information is
temporarily unavailable.

1-year stock price forecast

VTRS Competitors

$ Market cap P/E ratio $ Price 1d change 52-week range

Key terms